Back to News
Market Impact: 0.25
Acepodia Announces First Patient Dosed in Phase 1 Trial of ACE723, a Novel Dual-Payload Antibody-Drug Conjugate
Source: PR Newswire
Healthcare & BiotechTechnology & Innovation
Acepodia announced that ACE723, the first candidate from its AD2C platform, has entered human testing. The announcement marks a clinical-development milestone, but the provided article excerpt contains no trial results, financial details, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Magnificent 7 loses $1 trillion. The most eye-popping stats from Thursday's tech stock plunge
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Wall Street’s best post-midterm rally in 44 years lasted just one day—then $3 trillion vanished as chip stocks plunged over AI fears
- AI stocks plunge after election, driving down US markets
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Shield AI To Hit $28.8 Billion Value With $5.3 Billion Radar Acquisition